Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial
published in: Lancet Oncology Commission
date of publication: 2012-08
language: English
main subject: phase I clinical trial, pharmacodynamics, pharmacokinetics
Cites articles 18
Date
Title
Article - wd:Q27851852